<DOC>
	<DOCNO>NCT02408380</DOCNO>
	<brief_summary>This study investigate whether link disease activity/progression patient receive Gilenya expression putative biomarker signature patient multiple sclerosis .</brief_summary>
	<brief_title>Analysis Biomarker Signature Patients With Multiple Sclerosis ( MS ) Treated With Gilenya ( FTY720 )</brief_title>
	<detailed_description>Gilenya modulate expression sphingosine-1-phosphate receptor inhibits egress several lymphocyte subset lymph node . This result immunosuppression beneficial effect patient multiple sclerosis . Our laboratory report increased expression possible biomarker signature , consist TLR2 , TLR4 CCR1 , T-subset associate rapid MS progression . The investigator test whether significant proportion patient baseline upregulate biomarker signature one T-subsets , whether expression biomarker signature change treatment Gilenya whether expression level signature predict disease activity progression 12 month followup period . The investigator study patient already treat Gilenya neurologist already treat Gilenya part clinical trial sponsor Novartis Pharmaceuticals Canada . Patients treat Gilenya purpose study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Treatment Gilenya Subject 18 65 . Subject le 4 week discontinuation steroid treatment relapse . Subject communicate reliably investigator . Vulnerable subject exclude , namely patient define without freedom law ( e.g . prisoner administrative decision ) people hospitalize without consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>biomarker</keyword>
	<keyword>disease progression</keyword>
</DOC>